Improving cardiac outcomes after noncardiac surgery

[1] [Anonymous], 1986, Lancet, V2, P57

[2] Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (16): : 2073 - 2082

[3] Predictors of cardiac events after major vascular surgery -: Role of clinical characteristics, dobutamine echocardiography, and β-blocker therapy [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (14): : 1865 - 1873

[4] Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [J]. LANCET, 2000, 356 (9227) : 366 - 372

[5] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J]. HYPERTENSION, 2003, 42 (06) : 1206 - 1252

[6] The messenger under attack - Intimidation of researchers by special-interest groups [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (16) : 1176 - 1180

[7] NIFEDIPINE - DOSE-RELATED INCREASE IN MORTALITY IN PATIENTS WITH CORONARY HEART-DISEASE [J]. CIRCULATION, 1995, 92 (05) : 1326 - 1331

[8] β-blockers in chronic heart failure [J]. CIRCULATION, 2003, 107 (12) : 1570 - 1575

[9] Cardiac events in patients undergoing noncardiac surgery: Shifting the paradigm from noninvasive risk stratification to therapy [J]. ANNALS OF INTERNAL MEDICINE, 2003, 138 (06) : 506 - 511

[10] Placebo-control led trials and the Declaration of Helsinki [J]. LANCET, 2002, 359 (9314) : 1337 - 1340

[1] [Anonymous], 1986, Lancet, V2, P57

[2] Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (16): : 2073 - 2082

[3] Predictors of cardiac events after major vascular surgery -: Role of clinical characteristics, dobutamine echocardiography, and β-blocker therapy [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (14): : 1865 - 1873

[4] Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [J]. LANCET, 2000, 356 (9227) : 366 - 372

[5] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J]. HYPERTENSION, 2003, 42 (06) : 1206 - 1252

[6] The messenger under attack - Intimidation of researchers by special-interest groups [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (16) : 1176 - 1180

[7] NIFEDIPINE - DOSE-RELATED INCREASE IN MORTALITY IN PATIENTS WITH CORONARY HEART-DISEASE [J]. CIRCULATION, 1995, 92 (05) : 1326 - 1331

[8] β-blockers in chronic heart failure [J]. CIRCULATION, 2003, 107 (12) : 1570 - 1575

[9] Cardiac events in patients undergoing noncardiac surgery: Shifting the paradigm from noninvasive risk stratification to therapy [J]. ANNALS OF INTERNAL MEDICINE, 2003, 138 (06) : 506 - 511

[10] Placebo-control led trials and the Declaration of Helsinki [J]. LANCET, 2002, 359 (9314) : 1337 - 1340